$EIDX initiated at Buy at BTIG. PT $38
$EIGR prices offering. 4.5M shares at $11/share.
$MATN (fka $OXGN) Enters into Merger Agreement with Oncotelic
$AFMD AFM11 decision slightly delayed to Q2 as FDA wants to see clinical trial protocol which Co has already submitted to FDA:
$NTRA 5.3M share secondary priced at $19/share
JP $RARE presents a unique value proposition as a newly commercial orphan disease company with a staggered pipeline and an R&D engine that is both active (3 more IND filings expected in 2020) diverse in terms of modalities (gene therapy, mRNA/LNP,small molecule, ERT). Maintain OW